Lilly’s Mirikizumab Shows Superiority Vs. Cosentyx In Psoriasis

 
• By Joseph Haas

Lilly plans to file the anti-IL-23 antibody for approval in psoriasis based on two Phase III trials. The latest data head-to-head against IL-17 inhibitor Cosentyx may guide physicians on how to treat patients.

Two female fencing athletes fight on professional sports arena with spectators and lense-flares. Women wear unbranded sports clothes.
Lilly's mirikizumab showed superiority versus Consentyx in three 52-week measures

More from Clinical Trials

More from R&D